Company Description
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide.
The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.
It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women’s healthcare provider organizations.
Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Kathy Lee-Sepsick |
Contact Details
Address: 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 United States | |
| Phone | 770 500 3910 |
| Website | femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E105 |
| ISIN Number | US31447E1055 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick | Chief Executive Officer |
| Dov Elefant | Chief Financial Officer |
| Daniel Currie | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K/A | [Amend] Current report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |